VRX Stock: Valeant Pharmaceuticals International PT Set at $18.00 by Deutsche Bank

0
252

Deutsche Bank set a $18.00 price target on Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) in a research report report published on Sunday, December 3rd. The brokerage currently has a hold rating on the specialty pharmaceutical company’s stock.

A number of other equities research analysts also recently issued reports on VRX. HC Wainwright set a $17.00 price objective on shares of Valeant Pharmaceuticals International and gave the stock a hold rating in a research report on Wednesday, August 9th. Piper Jaffray Companies set a $14.00 price objective on shares of Valeant Pharmaceuticals International and gave the stock a sell rating in a research report on Wednesday, August 9th. Canaccord Genuity set a $14.00 target price on shares of Valeant Pharmaceuticals International and gave the company a hold rating in a research note on Thursday, August 10th. Wells Fargo & Company reiterated an underperform rating and issued a $8.00 target price on shares of Valeant Pharmaceuticals International in a research note on Saturday, September 30th. Finally, Rodman & Renshaw reiterated a neutral rating and issued a $17.00 target price on shares of Valeant Pharmaceuticals International in a research note on Thursday, August 10th. Six equities research analysts have rated the stock with a sell rating, ten have given a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. The company currently has an average rating of Hold and an average price target of $17.46.

Shares of Valeant Pharmaceuticals International (VRX) opened at $22.05 on Friday. Valeant Pharmaceuticals International has a 52-week low of $8.31 and a 52-week high of $22.81. The company has a debt-to-equity ratio of 4.84, a current ratio of 1.26 and a quick ratio of 1.03. The stock has a market cap of $7,623.71, a PE ratio of 3.56, a price-to-earnings-growth ratio of 0.59 and a beta of -0.22.

In related news, Director John Paulson purchased 344,216 shares of the firm’s stock in a transaction dated Thursday, November 16th. The shares were purchased at an average price of $14.40 per share, with a total value of $4,956,710.40. Following the acquisition, the director now directly owns 94,559 shares of the company’s stock, valued at $1,361,649.60. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 5.87% of the company’s stock.

Several large investors have recently modified their holdings of the company. Eaton Vance Management increased its holdings in shares of Valeant Pharmaceuticals International by 1.2% in the 2nd quarter. Eaton Vance Management now owns 43,469 shares of the specialty pharmaceutical company’s stock worth $752,000 after buying an additional 500 shares during the last quarter. IFP Advisors Inc increased its holdings in shares of Valeant Pharmaceuticals International by 0.4% in the 2nd quarter. IFP Advisors Inc now owns 128,305 shares of the specialty pharmaceutical company’s stock worth $2,220,000 after buying an additional 509 shares during the last quarter. Tocqueville Asset Management L.P. increased its holdings in shares of Valeant Pharmaceuticals International by 3.8% in the 2nd quarter. Tocqueville Asset Management L.P. now owns 21,914 shares of the specialty pharmaceutical company’s stock worth $379,000 after buying an additional 800 shares during the last quarter. Commonwealth Bank of Australia increased its holdings in shares of Valeant Pharmaceuticals International by 0.7% in the 2nd quarter. Commonwealth Bank of Australia now owns 108,806 shares of the specialty pharmaceutical company’s stock worth $1,887,000 after buying an additional 800 shares during the last quarter. Finally, Nationwide Fund Advisors increased its holdings in shares of Valeant Pharmaceuticals International by 1.7% in the 2nd quarter. Nationwide Fund Advisors now owns 52,400 shares of the specialty pharmaceutical company’s stock worth $907,000 after buying an additional 900 shares during the last quarter. 49.49% of the stock is currently owned by hedge funds and other institutional investors.

Valeant Pharmaceuticals International Company Profile

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Analyst Recommendations for Valeant Pharmaceuticals International (NYSE:VRX)

LEAVE A REPLY

Please enter your comment!
Please enter your name here